Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
US-2024337668-A1 · Oct 10, 2024 · US
Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
US9784751B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9784751-B2 |
| Application number | US-201214113385-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 25, 2012 |
| Priority date | Apr 25, 2011 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for detecting a neurological disease associated with cognitive impairment, wherein the extracellular domain of EphA4 is measured from a biological sample taken from a subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for measuring the presence or amount of the EphA4 extracellular domain, comprising: (a) providing a body fluid taken from a subject having or suspected of having Alzheimer's disease or mild cognitive impairment; (b) contacting the body fluid with an antibody that specifically binds to the extracellular domain of EphA4; and (c) measuring the presence or amount of the EphA4 extracellular domain in the body fluid. 2. The method according to claim 1 , wherein the body fluid is at least one selected from the group consisting of blood, serum, plasma, urine, spinal fluid, saliva, lacrimal fluid and sweat. 3. The method according to claim 1 , wherein the body fluid is serum or plasma. 4. The method according to claim 1 , wherein the presence or amount of the EphA4 extracellular domain is measured by ELISA.
Assignees
Inventors
Classifications
Receptor protein-tyrosine kinase (2.7.10.1) · CPC title
- G01N33/6896Primary
Neurological disorders, e.g. Alzheimer's disease · CPC title
Alzheimer · CPC title
transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title
Dementia; Cognitive disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9784751B2 cover?
- A method for detecting a neurological disease associated with cognitive impairment, wherein the extracellular domain of EphA4 is measured from a biological sample taken from a subject.
- Who is the assignee on this patent?
- Obara Takashi, Inoue Eiji, Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6896. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).